Giuseppe Curigliano is internationally recognized for his expertise in early-phase drug development and translational research in solid tumors, with a particular focus on breast cancer. A Full Professor of Medical Oncology at the University of Milan and Chief of the Division of Early Drug Development at the European Institute of Oncology (IEO), Milan, one of the world’s leading comprehensive cancer centers, he has played a pivotal role in the development of multiple anticancer therapies that are now part of standard clinical practice, integrating molecular profiling, pharmacogenomics, and precision medicine approaches into clinical care.
He is credited with landmark trials advancing HER2-targeted therapies and antibody–drug conjugates, directly shaping modern standards of care in early and metastatic breast cancer. He is the President-Elect of the European Society for Medical Oncology (ESMO) for 2027-2028 and a mentor to many rising stars in oncology worldwide.
The 100 Most Influential People in Oncology in 2025 recognizes the changemakers in cancer care who have helped shape current practice in oncology and continue to drive innovation and research towards better outcomes, advocacy, philanthropy, leadership, and education. For the many deserving individuals not mentioned in this list, we will continue to acknowledge, honor, and elevate your voices in our daily publications from across the world.
See the full list of The 100 Influential People in Oncology in 2025 and stay tuned for the results of special category nominations to be announced.
